We are proud to announce that we will exhibit at the Osaka Healthcare Pavilion ……
Press Release
We are pleased to announce that we have successfully completed the first shipme……
December 25th, 2024
Stella Pharma Concludes MOU on Boron Neutron Capture Therapy System with Fujita Health University, Atransen Pharma, SHI, and Fujita
Stella Pharma Corporation has concluded a Memorandum of Understanding (MOU) to ……
December 10th, 2024
Observation Period Completed for Primary Endpoint – Phase II Clinical Trial in Patients with Angiosarcoma
We are pleased to announce the completion of the 90-day observation period for ……
December 6th, 2024
Paper published: Poly(vinyl alcohol) Potentiating an Inert D-Amino Acid-Based Drug for Boron Neutron Capture Therapy
The paper titled “Poly(vinyl alcohol) potentiating an inert D-amino acid-based ……
November 14th, 2024
Announcement of Agreement Conclusion with TAE LIFE SCIENCES for Collaboration in the Development and Commercialization of BPA Drug for BNCT in Europe and the US
STELLA PHARMA CORPORATION announced today that our Company has entered into a D……
September 25th, 2024
Orphan Drug Designation for Borofalan (10B) (SPM-011) as treatment of Recurrent Malignant Glioma and Recurrent Meningioma
Our product Borofalan (10B) (development code: SPM-011), which we are developin……
September 10th, 2024
Patient Enrollment Completed for Phase II Clinical Trial in Japan on Angiosarcoma
Stella Pharma completed the enrollment of patients for the domestic phase II do……
September 6th, 2024
Conclusion of an Agreement with the National Cancer Center, Sumitomo Heavy Industries, Ltd. and CICS, Inc. for Clinical Trial of BNCT
Stella Pharma announces that it has signed an agreement with the National Cance……
August 30th, 2024
Application for Orphan Drug Designation: Borofalan (10B) for Recurrent Malignant Glioma and Recurrent Meningioma
Stella Pharma announces that it has applied to the Japanese Ministry of Health,……
July 16th, 2024
Specified Clinical Research Contract concluded with Edogawa Hospital
― Providing our drug for Research on FDG-PET-positive shallow tumors ― Stell……
June 24th, 2024
BNCT for Thoracic Malignant Tumor – Submission of Trial Plan Notification for Domestic Clinical Trial Phase I/II
We would like to announce that our company submitted the trial plan notificatio……
